The AMR Action Fund is the world's largest venture capital fund dedicated to investing in urgently needed antimicrobial therapeutics. It makes equity investments in small and mid-size biotech companies developing treatments for patients suffering from life-threatening antimicrobial-resistant infections.
60% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-b (40% of deals).
Portfolio
5
Fund Size
$1B
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Centauri Therapeutics | Series A | — | Feb 2026 |
| TTenNor Therapeutics | Series E | — | Oct 2024 |
 Elion Therapeutics | Series B | $81M | Jun 2024 |
| FF2G | Series H | $100M | Jan 2024 |
 ANTABIO | Series B | — | Jul 2017 |
Top Co-Investors
Illinois Ventures1 shared
Deerfield1 shared
Boehringer Ingelheim Venture Fund1 shared
Forbion1 shared
Sofinnova Partners1 shared
Novo Capital1 shared
Last updated: 7 September 2026